Compare Amgen, Inc. (AMGN) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Riot Platforms Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Riot Platforms Inc trades at $20.7 (market cap $7.93B). The key difference: Amgen, Inc. is far larger — about 24.7× Riot Platforms Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| AMGN | RIOT | |
|---|---|---|
Market Cap | $196.12B | $7.93B |
Sector | Health | Technology |
52-Week High | $388.16 | $28.67 |
52-Week Low | $271.18 | $11.03 |
Enterprise Value | $241.41B | $8.60B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RIOT trades at $20.97, down 2.58% today, with a bearish technical signal. Recent earnings show mixed results, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. The company reported a net loss of $663 million in 2025 despite $647 million revenue. Analyst consensus is strongly bullish with a $27.86 price target. News highlights volatility tied to Bitcoin trends and a strategic pivot toward AI data centers.
Outlook remains speculative with high valuation multiples amid persistent losses. Opportunities include expansion into high-performance computing, but risks involve cash flow deficits, competitive pressures, and sensitivity to cryptocurrency markets. Investors should weigh analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
